AbbVie Statistics
Total Valuation
AbbVie has a market cap or net worth of $310.27 billion. The enterprise value is $374.31 billion.
| Market Cap | 310.27B |
| Enterprise Value | 374.31B |
Important Dates
The next estimated earnings date is Friday, January 31, 2025, before market open.
| Earnings Date | Jan 31, 2025 |
| Ex-Dividend Date | Jan 15, 2025 |
Share Statistics
AbbVie has 1.77 billion shares outstanding. The number of shares has decreased by -0.07% in one year.
| Current Share Class | 1.77B |
| Shares Outstanding | 1.77B |
| Shares Change (YoY) | -0.07% |
| Shares Change (QoQ) | +0.06% |
| Owned by Insiders (%) | 0.07% |
| Owned by Institutions (%) | 73.01% |
| Float | 1.76B |
Valuation Ratios
The trailing PE ratio is 61.18 and the forward PE ratio is 14.64. AbbVie's PEG ratio is 1.66.
| PE Ratio | 61.18 |
| Forward PE | 14.64 |
| PS Ratio | 5.59 |
| Forward PS | 5.20 |
| PB Ratio | 51.44 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 19.86 |
| P/OCF Ratio | 18.79 |
| PEG Ratio | 1.66 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 14.60, with an EV/FCF ratio of 23.96.
| EV / Earnings | 73.67 |
| EV / Sales | 6.74 |
| EV / EBITDA | 14.60 |
| EV / EBIT | 21.67 |
| EV / FCF | 23.96 |
Financial Position
The company has a current ratio of 0.65, with a Debt / Equity ratio of 11.75.
| Current Ratio | 0.65 |
| Quick Ratio | 0.44 |
| Debt / Equity | 11.75 |
| Debt / EBITDA | 2.75 |
| Debt / FCF | 4.57 |
| Interest Coverage | 6.47 |
Financial Efficiency
Return on equity (ROE) is 56.41% and return on invested capital (ROIC) is 14.32%.
| Return on Equity (ROE) | 56.41% |
| Return on Assets (ROA) | 7.72% |
| Return on Capital (ROIC) | 14.32% |
| Revenue Per Employee | $1.11M |
| Profits Per Employee | $101,620 |
| Employee Count | 50,000 |
| Asset Turnover | 0.40 |
| Inventory Turnover | 3.91 |
Taxes
In the past 12 months, AbbVie has paid $2.06 billion in taxes.
| Income Tax | 2.06B |
| Effective Tax Rate | 28.68% |
Stock Price Statistics
The stock price has increased by +14.31% in the last 52 weeks. The beta is 0.56, so AbbVie's price volatility has been lower than the market average.
| Beta (5Y) | 0.56 |
| 52-Week Price Change | +14.31% |
| 50-Day Moving Average | 182.76 |
| 200-Day Moving Average | 178.83 |
| Relative Strength Index (RSI) | 46.96 |
| Average Volume (20 Days) | 6,833,239 |
Short Selling Information
The latest short interest is 19.32 million, so 1.09% of the outstanding shares have been sold short.
| Short Interest | 19.32M |
| Short Previous Month | 18.13M |
| Short % of Shares Out | 1.09% |
| Short % of Float | 1.10% |
| Short Ratio (days to cover) | 2.46 |
Income Statement
In the last 12 months, AbbVie had revenue of $55.53 billion and earned $5.08 billion in profits. Earnings per share was $2.87.
| Revenue | 55.53B |
| Gross Profit | 39.06B |
| Operating Income | 17.27B |
| Pretax Income | 7.06B |
| Net Income | 5.08B |
| EBITDA | 25.63B |
| EBIT | 17.27B |
| Earnings Per Share (EPS) | $2.87 |
Balance Sheet
The company has $7.29 billion in cash and $71.32 billion in debt, giving a net cash position of -$64.04 billion or -$36.24 per share.
| Cash & Cash Equivalents | 7.29B |
| Total Debt | 71.32B |
| Net Cash | -64.04B |
| Net Cash Per Share | -$36.24 |
| Equity (Book Value) | 6.07B |
| Book Value Per Share | 3.41 |
| Working Capital | -15.28B |
Cash Flow
In the last 12 months, operating cash flow was $16.51 billion and capital expenditures -$888.00 million, giving a free cash flow of $15.62 billion.
| Operating Cash Flow | 16.51B |
| Capital Expenditures | -888.00M |
| Free Cash Flow | 15.62B |
| FCF Per Share | $8.84 |
Margins
Gross margin is 70.33%, with operating and profit margins of 31.10% and 9.22%.
| Gross Margin | 70.33% |
| Operating Margin | 31.10% |
| Pretax Margin | 12.96% |
| Profit Margin | 9.22% |
| EBITDA Margin | 46.15% |
| EBIT Margin | 31.10% |
| FCF Margin | 28.13% |
Dividends & Yields
This stock pays an annual dividend of $6.56, which amounts to a dividend yield of 3.74%.
| Dividend Per Share | $6.56 |
| Dividend Yield | 3.74% |
| Dividend Growth (YoY) | 5.01% |
| Years of Dividend Growth | 52 |
| Payout Ratio | 228.58% |
| Buyback Yield | 0.07% |
| Shareholder Yield | 3.81% |
| Earnings Yield | 1.64% |
| FCF Yield | 5.04% |
Analyst Forecast
The average price target for AbbVie is $207.45, which is 18.15% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $207.45 |
| Price Target Difference | 18.15% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 22 |
| Revenue Growth Forecast (5Y) | 5.91% |
| EPS Growth Forecast (5Y) | 37.06% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AbbVie has an Altman Z-Score of 1.9 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.9 |
| Piotroski F-Score | 5 |